Skip to main content

Eli Lilly vs Novo Nordisk: Founders, CEOs and History

Eli Lilly was founded in 1876 by Colonel Eli Lilly and is led by David A. Ricks. Novo Nordisk was founded in 1989 by Hans Christian Hagedorn, Harald Pedersen and is led by Maziar Mike Doustdar.

Company facts

Eli Lilly

Founded
1876
Headquarters
Indianapolis, Indiana
Current CEO
David A. Ricks
Employees
50,000

Novo Nordisk

Founded
1989
Headquarters
Bagsvaerd, Denmark
Current CEO
Maziar Mike Doustdar
Employees
66,700

Founders

Eli Lilly

  • Colonel Eli Lilly

    Following his military service and early experiences in the apothecary trade, Lilly worked in various pharmaceutical and business ventures, eventually amassing enough capital to strike out on his own.

Eli Lilly founders in full

Novo Nordisk

  • Hans Christian Hagedorn

    Hans Christian Hagedorn (1888-1971) was a Danish physician who co-founded Nordisk Insulinlaboratorium in 1923 with August and Marie Krogh after the Kroghs obtained rights to make insulin in Scandinavia.

  • Harald Pedersen

    Harald Pedersen and his brother Thorvald worked at Nordisk Insulinlaboratorium before a 1924 dispute led them to set up Novo Terapeutisk Laboratorium in Copenhagen in 1925.

Novo Nordisk founders in full

CEOs and their tenures

Eli Lilly

  1. Randall L. Tobias1993–1998

    Chairman and Chief Executive Officer

    Lilly launched Zyprexa and Humalog under him. Sidney Taurel succeeded him in 1998.

    Source
  2. Sidney Taurel1998–2008

    Former Chair and CEO

    Taurel's focus on targeted, personalized medicine anticipated the future direction of the pharmaceutical industry, shifting the company's research paradigm toward more precise and effective treatments.

    Source
  3. John C. Lechleiter2008–2016

    Chairman, President and CEO

    Lilly restructured and launched new products during his tenure. David Ricks became chief executive in 2017.

    Source
  4. David A. Ricks2017–present

    Chair and Chief Executive Officer

    Ricks's aggressive restructuring and cultural overhaul have been widely credited with revitalizing Eli Lilly's pipeline and driving a notable period of financial growth and market capitalization expansion.

    Source
Eli Lilly CEO history in full

Novo Nordisk

  1. Lars Rebien Sørensen2000–2016

    Chief Executive Officer

    Serving as CEO from 2000 to 2016, he laid the absolutely critical, foundational R&D groundwork for GLP-1 agonists that would eventually lead to the massive global explosion of Ozempic and Wegovy.

    Source
  2. Lars Fruergaard Jørgensen2017–2025

    Chief Executive Officer

    CEO from January 2017 to August 2025. Oversaw the launches of Ozempic, Rybelsus and Wegovy and large capacity investments, then was replaced by the board in 2025 after share losses to Eli Lilly and a cut to guidance.

    Source
  3. Maziar Mike Doustdar2025–present

    President and Chief Executive Officer

    Became CEO on August 7, 2025, succeeding Lars Fruergaard Jørgensen. Joined Novo Nordisk in 1992 and previously ran International Operations, where sales more than doubled over a decade. First non-Danish CEO in the company's history.

    Source
  4. Lars Rebien Sørensen2025–present

    Chair of the Board

    Serving as CEO from 2000 to 2016, he laid the absolutely critical, foundational R&D groundwork for GLP-1 agonists that would eventually lead to the massive global explosion of Ozempic and Wegovy.

    Source
Novo Nordisk CEO history in full

Timeline: Eli Lilly and Novo Nordisk side by side

  1. 1876Eli Lilly

    Eli Lilly Founded

    Colonel Eli Lilly founds the company in Indianapolis.

  2. 1923Eli Lilly

    Insulin Commercialization

    Lilly helps commercialize insulin at industrial scale, shaping its long-term diabetes identity.

  3. 1923Novo Nordisk

    Founding of Nordisk Insulinlaboratorium

    August Krogh and Hans Christian Hagedorn founded the Nordisk Insulinlaboratorium in Copenhagen, securing the licensing rights to produce insulin for the Scandinavian countries.

  4. 1925Novo Nordisk

    Founding of Novo Terapeutisk Laboratorium

    Harald Pedersen and a group of Danish physicians founded Novo Terapeutisk Laboratorium to produce insulin and other biological products using industrial-scale fermentation processes.

  5. 1950Eli Lilly

    Antibiotic Expansion

    The company expands through antibiotics and broader prescription medicines.

  6. 1982Eli Lilly

    Humulin Approved

    Lilly introduces Humulin, one of the first recombinant DNA human insulin products.

  7. 1989Novo Nordisk

    Merger of Novo and Nordisk

    The $1.5 billion merger of Novo Industri and Nordisk Insulinlaboratorium was completed, creating Novo Nordisk A/S as one of the world's largest insulin manufacturers.

  8. 2005Novo Nordisk

    Launch of Insulin detemir (Levemir)

    Novo Nordisk launched Insulin detemir, a long-acting basal insulin analog with a flat action profile and reduced risk of hypoglycemia compared to NPH insulin.

  9. 2009Novo Nordisk

    Launch of Victoza (liraglutide)

    Novo Nordisk launched Victoza, the first once-daily GLP-1 receptor agonist, marking the company's strategic pivot from insulin to incretin-based therapies.

  10. 2017Eli Lilly

    David Ricks Becomes CEO

    David A. Ricks becomes Chair, President, and CEO.

  11. 2017Novo Nordisk

    Launch of Ozempic (semaglutide)

    Novo Nordisk launched Ozempic, a once-weekly GLP-1 receptor agonist for type 2 diabetes, which became the fastest-growing diabetes drug in history.

  12. 2019Eli Lilly

    Loxo Oncology Acquired

    Lilly bought the cancer-drug developer Loxo Oncology in 2019 for about $8 billion.

  13. 2021Novo Nordisk

    Launch of Wegovy (semaglutide 2.4mg)

    Novo Nordisk launched Wegovy, a high-dose formulation of semaglutide for chronic weight management, demonstrating an average weight loss of 14.9% in the STEP-1 trial.

  14. 2022Eli Lilly

    Mounjaro Approved

    Mounjaro receives U.S. approval for type 2 diabetes, beginning a major growth cycle.

  15. 2023Eli Lilly

    Zepbound Approved

    Zepbound receives U.S. approval for chronic weight management.

  16. 2023Novo Nordisk

    SELECT Trial Results

    Novo Nordisk announced the results of the SELECT trial, demonstrating a 20% reduction in major adverse cardiovascular events for semaglutide 2.4mg in non-diabetic obese patients.

  17. 2024Novo Nordisk

    Catalent Acquisition

    Novo Holdings completed its $16.5 billion acquisition of Catalent in December 2024, and Novo Nordisk bought three Catalent fill-finish sites in Italy, Belgium and Indiana for $11 billion to expand Wegovy and Ozempic capacity.

  18. 2024Novo Nordisk

    FY2024 Financial Results

    Novo Nordisk reported FY2024 net sales of ~$44.1 billion (DKK 290.4 billion), up 25% in DKK, and net profit of ~$15.4 billion (DKK 101.0 billion).

  19. 2025Eli Lilly

    Revenue Reaches $65.179B

    Lilly reports $65.179B in 2025 revenue and $20.640B in net income.

  20. 2025Eli Lilly

    First $1 Trillion Drugmaker

    Lilly's market value crosses $1 trillion on November 21, 2025, a first for a healthcare company.

  21. 2025Novo Nordisk

    CEO Change and Restructuring

    Mike Doustdar replaced Lars Fruergaard Jørgensen as CEO on August 7, 2025, and in September the company announced about 9,000 job cuts. Lars Rebien Sørensen later became board chair after a dispute with the Novo Nordisk Foundation over board composition.

  22. 2026Eli Lilly

    Foundayo Approved

    FDA approves Foundayo (orforglipron), Lilly's oral GLP-1 pill for obesity, on April 1, 2026.

  23. 2026Novo Nordisk

    Wegovy Pill Launch

    After FDA approval in December 2025, Novo launched the oral Wegovy pill in the US in January 2026; it passed 5 million prescriptions by August 2026 and received EU approval in July 2026.

  24. 2026Novo Nordisk

    Capital Markets Day

    On September 21, 2026 Novo set 2030 targets of mid-single-digit sales growth and more than five multi-blockbuster launches; the shares fell about 8%.

Acquisitions

Eli Lilly

  • Morphic Holding2024$3.2B
  • POINT Biopharma2023$1.4B
  • Prevail Therapeutics2021$1B
  • Loxo Oncology2019$8B
  • Elizabeth Arden1971Undisclosed
All Eli Lilly acquisitions

Novo Nordisk

  • Akero Therapeutics2025$5.2B
  • Three Catalent fill-finish sites2024$11B
  • Dicerna Pharmaceuticals2021$3.3B
All Novo Nordisk acquisitions

Questions about Eli Lilly vs Novo Nordisk

Who is the CEO of Eli Lilly and Company and Novo Nordisk A/S?

Eli Lilly and Company is led by David A. Ricks and Novo Nordisk A/S is led by Maziar Mike Doustdar. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.

When was Eli Lilly and Company founded vs Novo Nordisk A/S?

Eli Lilly and Company was founded in 1876 — 113 years before Novo Nordisk A/S, which was founded in 1989. Eli Lilly and Company's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Novo Nordisk A/S.

How many employees does Eli Lilly and Company have compared to Novo Nordisk A/S?

Eli Lilly and Company employs approximately 50,000 people, while Novo Nordisk A/S employs approximately 66,700. Novo Nordisk A/S has the larger workforce at 66,700 employees, compared to Eli Lilly and Company's 50,000. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).

Where are Eli Lilly and Company and Novo Nordisk A/S headquartered?

Eli Lilly and Company is headquartered in United States and Novo Nordisk A/S is headquartered in Denmark. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.

Who founded Eli Lilly and Company and Novo Nordisk A/S?

Eli Lilly and Company was founded by Colonel Eli Lilly. Novo Nordisk A/S was founded by Hans Christian Hagedorn, Harald Pedersen.

Which company has a longer operating history — Eli Lilly and Company or Novo Nordisk A/S?

Eli Lilly and Company has been operating for approximately 150 years, making it the more established of the two companies. Novo Nordisk A/S has been in operation for around 37 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.

Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Eli Lilly vs Novo Nordisk overview

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.